Şiddetli Covid–19 Hastasında Erken Hemoperfüzyon Uygulanması ile Akut Solunum Yetmezliğinin Başarılı İyileşmesi: Vaka Sunumu

Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223): 497–506.

Fajgenbaum DC, June CH. Cytokine Storm. The New England journal of medicine, 2020 Dec 3;383(23):2255-2273. doi: 10.1056/NEJMra2026131.

RECOVERY Collaborative Group; Horby P, Lim WS, Emberson JR, et al. Dexamethasone in Hospitalized Patients with Covid-19. The New England journal of medicine. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436.

Clark EG, Hiremath S, McIntyre L, et al. Haemoperfu-sion should only be used for COVID-19 in the context of randomized trials. Nature reviews. Nephrology. 2020; 16(12): 697–699. https://doi.org/10.1038/s41581-020-00352-9

Nkawi G, Fan W, Pomarè Montin D, et al. A new series of sorbent devices for multiple clinical pur-poses: current evidence and future directions. Blood purificationood . 2019; 47(1–3): 94–100.

FDA Emergency Use Authorization approval documents. 2020. Available from: https: //www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization# covidothermedde.other

Shadvar K, Tagizadiyeh A, Gamari AA, et al. Hemoperfusion as a potential treatment for critically ill COVID-19 patients with cytokine storm. Blood purification, 2021;50(3), 405–407. https://doi.org/10.1159/000511391 .

Surasit K, Srisawat N. The Efficacy of Early Additional Hemoperfusion Therapy for Severe COVID-19 Patients: A Prospective Cohort Study. Blood purification 2022 51(11):879-888.doi: 10.1159/000521713.

Abbasi S, Naderi Z, Amra B, et al. Hemoperfusion in patients with severe COVID-19 respiratory failure, lifesaving or not? Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences, 2021;26(1):34. doi:10.4103/jrms.JRMS_1122_20

Esmaeili Vardanjani A, Ronco C, Rafiei H,et al. Early hemoperfusion for cytokine removal may contribute to prevention of intubation in patients infected with COVID-19. Blood purification 2021;50(2):257–260 doi:10.1159/000509107

Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell .2021; 184(4):861–880. doi: 10.1016/j.cell.2021.01.007

Karki R, Kanneganti TD. Innate immunity, cytokine storm, and inflammatory cell death in COVID-19. Journal of translational medicine 2022; 20(1):542. doi: 10.1186/s12967-022-03767-z

Kasuga Y, Zhu B, Jang KJ, et al. Innate immune sensing of coronavirus and viral evasion strategies. Experimental & molecular medicine. 2021; 53(5):723–736. doi: 10.1038/s12276-021-00602-1

Mathew D, Giles JR, Baxter AE, et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science(New York NY). 2020; 369(6508): eabc8511 doi: 10.1126/science.abc8511.

Ramasamy S, Subbian S. Critical determinants of cytokine storm and type I interferon response in COVID-19 pathogenesis. Clinical microbiology reviews, 2021; 34(3): e00299-20. doi: 10.1128/CMR.00299-20

Alam MS, Czajkowsky DM. SARS-CoV-2 infection and oxidative stress:Pathophysiological insight into thrombosis and therapeutic opportunities. Cytokine & growth factor reviews, 2022; 63:44–57. doi: 10.1016/j.cytogfr.2021.11.001

Prasad M, Leon M, Lerman LO, et al. Viral endothelial dysfunction: A unifying mechanism for COVID-19. Mayo Clinic proceedings, 2021; 96(12):3099–3108. doi: 10.1016/j.mayocp.2021.06.027

Merad M, Martin JC. Pathological inflammation in patients with COVID-19: A key role for monocytes and macrophages. Nature reviews. Immunology, 2020; 20(6):355–62. doi: 10.1038/s41577-020-0331-4

Mehta Y, Dixit SB, Zirpe KG, et al. Cytokine storm in novel coronavirus disease (COVID-19): Expert management considerations. Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine, 2020; 24(6):429–434. doi: 10.5005/jp-journals-10071-23415

Mahdavi M, Hejri GM, Pouraliakbar H,et al. Cytokine storm after heart transplantation in COVID-19-related haemophagocytic lymphohistiocytosis (HLH). ESC Heart failure 2022; 9(1):219–223. doi: 10.1002/ehf2.13728

Lalwani P, Baskaran S, Uribe DA, , et al. A case of COVID-19-Associated pediatric multisystem inflammatory syndrome in shock managed by cytokine filtration. Case reports in pediatrics. 2022; 3373289. doi: 10.1155/2022/3373289

Tay MZ, Poh CM, Renia L, et al. The trinity of COVID-19: immunity, inflammation and intervention. Nature reviews. Immunology 2020; 20(6):363–374. doi: 10.1038/s41577-020-0311-8

Wolley M, Jardine M, Hutchison CA. Exploring the clinical relevance of providing increased removal of Large middle molecules. Clinical journal of the American Society of Nephrology : CJASN. 2018; 13(5):805–814. doi: 10.2215/CJN.10110917

Ronco C, Bellomo R. Hemoperfusion: technical aspects and state of the art. Critical care (London, England). 2022; 26(1):135. doi: 10.1186/s13054-022-04009-w

Ronco C, Bellomo R. Acute renal failure and multiple organ dysfunction in the ICU: from renal replacement therapy (RRT) to multiple organ support therapy (MOST). The International journal of artificial organs. 2002; 25(8):733–747. doi: 10.1177/039139880202500801

Supady A, Weber E, Rieder M, et al. Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation (CYCOV): A single centre, open-label, randomised, controlled trial. The Lancet. Respiratory medicine. 2021; 9(7):755–762. doi: 10.1016/S2213-2600(21)00177-6

Guo J, Xia H, Wang S, et al. The artificial-liver blood-purification system can effectively improve hypercytokinemia for COVID-19. Frontiers in immunology 2020; 11:586073. doi: 10.3389/fimmu.2020.586073

Peng Z, Singbartl K, Simon P, et al. Blood purification in sepsis: A new paradigm. Contributions to nephrology. 2010; 165:322–8. doi: 10.1159/000313773

Lancman G, Mascarenhas J, Bar-Natan M. Severe COVID-19 virus reactivation following treatment for b cell acute lymphoblastic leukemia. Journal of hematology & oncology. 2020; 13(1):131. doi: 10.1186/s13045-020-00968-1

Yessayan LT, Neyra JA, Westover AJ, et al. Extracorporeal immunomodulation treatment and clinical outcomes in ICU COVID-19 patients. Critical care explorations. 2022; 4(5):e0694. doi: 10.1097/CCE.0000000000000694

Tampe D, Korsten P, Bremer SCB, et al. Kinetics of bilirubin and ammonia elimination during hemadsorption therapy in secondary sclerosing cholangitis following ECMO therapy and severe COVID-19. Biomedicines . 2021; 9(12): 1841. doi: 10.3390/biomedicines9121841

Holubek WJ, Hoffman RS, Goldfarb DS et al. Use of hemodialysis and hemoperfusion in poisoned patients. Kidney international.2028; 74:1327–1334. https://doi.org/10.1038/ki.2008.462

Shalkham AS, Kirrane BM, Hoffman RS et al. The availability and use of charcoal hemoperfusion in the treatment of poisoned patients. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2006;48:239–241. https://doi.org/10.1053/j.ajkd.2006.04.080

Winchester JF, Kellum JA, Ronco C et al. Sorbents in acute renal failure and the systemic inflammatory response syndrome. Blood purification. 2003;21:79–84. https://doi.org/10.1159/000067860

Peng, Z., Singbartl, K., Simon, P., et al. Blood purification in sepsis: a new paradigm. Contributions to nephrology. 2010;165,322–328.

Ricci Z, Romagnoli S, Reis T, et al. Hemoperfusion in the intensive care unit. Intensive care medicine. 2022; 48(10), 1397–1408.https://doi.org/10.1007/ s00134-022-06810-1

Ankawi G, Fan W, Pomarè Montin D, et al. A new series of sorbent devices for multiple clinical purposes: Current evidence and future directions. Blood Purification .2019; 47(1-3):94–100. doi: 10.1159/000493523

Pomarè Montin D, Ankawi G, Lorenzin A,et al. Biocompatibility and cytotoxic evaluation of new sorbent cartridges for blood hemoperfusion. Blood Purification. 2018; 46(3):187–195. doi: 10.1159/000489921

Lezhnina A, Lem V, Blatt N. Application of extracorporeal apheresis in treatment of COVID-19: A rapid review. BioNanoScience .2022; 12(3):979–93. doi: 10.1007/s12668- 022-00987-x

Chang K, Li Y, Qin Z, Zhang Z, et al. Effect of extracorporeal hemoadsorption in critically ill patients with COVID-19: A narrative review. Frontiers in immunology. 2023; Feb 3;14:1074465. doi: 10.3389/fimmu.2023.1074465.

Alavi Darazam I, Kazempour M, Pourhoseingholi MA, et al. Efficacy of hemoperfusion in severe and critical cases of COVID-19. Blood purification. 2023; 52(1), 8–16. doi:10.1159/000524606

Abdullayev R, Gul F, Bilgili B,et al. Cytokine adsorption in critically ill COVID-19 patients, a case-control study. Journal of intensive care medicine. 2022; 37(9):1223–1228. doi:10.1177/08850666221085185

Li Y, Han M, Yang M et al. Hemoperfusion with the HA330/HA380 cartridge in intensive care settings: a state-of-the-art review. Blood purification. 2024; 54(2), 122–137. https://doi.org/10.1159/000542469

He Z, Lu H, Jian X et al. The efficacy of resin hemoperfusion cartridge on inflammatory responses during adult cardiopulmonary bypass. Blood purification.2022; 51:31–37. https://doi.org/10.1159/000514149

Waalders NJB, Kox M, Pickkers P. Haemoadsorption to remove inflammatory mediators in sepsis: past, present, and future. Intensive care medicine experimental. 2025; 21;13(1):38. doi: 10.1186/s40635-025-00740-0.

Köhler T, Schwier E, Praxenthaler J, et al. Therapeutic modulation of the host defense by hemoadsorption with CytoSorb®)-basics, indications and perspectives-a scoping review. International journal of molecular sciences. 2021; 22(23):12786. doi: 10.3390/ijms222312786

Sekandarzad A, Weber E, Prager EP, et al. Cytokine adsorption in patients with acute-on-chronic liver failure (CYTOHEP)-a single center, open-label, three-arm, randomized, controlled intervention trial. Trials.2022; 23 (1):222. doi: 10.1186/s13063-022-06139-6

Eichhorn T, Rauscher S, Hammer C, et al. Polystyrene-Divinylbenzene-Based adsorbents reduce endothelial activation and monocyte adhesion under septic conditions in a pore size-dependent manner. Inflammation. 2016; 39(5):1737–1746. doi: 10.1007/s10753-016-0408-1

Gruda MC, Ruggeberg KG, O'Sullivan P, et al. Broad adsorption of sepsis-related PAMP and DAMP molecules, mycotoxins, and cytokines from whole blood using CytoSorb sorbent porous polymer beads. PloS One. 2018; 13(1):e0191676. doi: 10.1371/journal.pone.0191676

Song T, Hayanga J, Durham L, et al. CytoSorb therapy in COVID-19 (CTC) patients requiring extracorporeal membrane oxygenation: A multicenter, retrospective registry. Frontiers in medicine. 2021;8:773461. doi: 10.3389/fmed.2021.773461

Stockmann H, Thelen P, Stroben F, et al. CytoSorb rescue for COVID-19 patients with vasoplegic shock and multiple organ failure: A prospective, open-label, randomized controlled pilot study. Critical care medicine. 2022; 50 (6):964–976. doi: 10.1097/CCM.0000000000005493

Diab M, Lehmann T, Bothe W, et al. Cytokine hemoadsorption during cardiac surgery versus standard surgical care for infective endocarditis (REMOVE): Results from a multicenter randomized controlled trial. Circulation. 2022; 145(13):959–968. doi: 10.1161/CIRCULATIONAHA.121.056940

Holme’n A, Corderfeldt A, Lannemyr L,et al. Whole blood adsorber during CPB and need for vasoactive treatment after valve surgery in acute endocarditis: A randomized controlled study. Journal of cardiothoracic and vascular anesthesia. 2022; 36(8 Pt B):3015–3020. doi: 10.1053/j.jvca.2022.02.028

Rasch S, Sancak S, Erber J, et al. Influence of extracorporeal cytokine adsorption on hemodynamics in severe acute pancreatitis: Results of the matched cohort pancreatitis cytosorbents inflammatory cytokine removal (PACIFIC) study. Artificial organs. 2022; 46(6):1019–1026. doi: 10.1111/aor.14195

Supady A, Zahn T, Kuhl M, et al. Cytokine adsorption in patients with post-cardiac arrest syndrome after extracorporeal cardiopulmonary resuscitation (CYTER) - a single-centre, open-label, randomised, controlled trial. Resuscitation. 2022; 173:169–178. doi: 10.1016/j.resuscitation.2022.02.001

Brouwer WP, Duran S, Kuijper M, et al. Hemoadsorption with CytoSorb shows a decreased observed versus expected 28-day all-cause mortality in ICU patients withseptic shock: A propensity-score-weighted retrospective study. Critical care. 2019;23(1):317. doi: 10.1186/s13054-019-2588-1

Pieri M, Fominskiy E, Nardelli P, et al. CytoSorb purification in critically ill SARS-CoV-2 patients. The International journal of artificial organs .2022; 45(2):216–220. doi: 10.1177/03913988211052572

Ruiz-Rodrı guez JC, Chiscano-Camo’n L, Ruiz-Sanmartin A, et al. Cytokine hemoadsorption as rescue therapy for critically ill patients with SARS-CoV-2 pneumonia with severe respiratory failure and hypercytokinemia. Frontiers in medicine. 2021; 8:779038. doi: 10.3389/ fmed.2021.779038

Nassiri AA, Hakemi MS, Miri MM, et al. Blood purification with CytoSorb in critically ill COVID-19 patients: A case series of 26 patients. Artificial organs. 2021; 45(11):1338–47. doi: 10.1111/aor.14024

Wunderlich-Sperl F, Kautzky S, Pickem C, et al. Adjuvant hemoadsorption therapy in patients with severe COVID-19 and related organ failure requiring CRRT or ECMO therapy: A case series. The International journal of artificial organs. 2021; 44(10):694–702. doi: 10.1177/03913988211030517

Vira’g M, Rottler M, Ocskay K, et al. Extracorporeal cytokine removal in critically ill COVID-19 patients: A case series. Frontiers in medicine. 2021; 8:760435. doi: 10.3389/fmed.2021.760435

Jarczak D, Roedl K, Fischer M, et al. Effect of hemadsorption therapy in critically ill patients with COVID-19 (CYTOCOV-19): A prospective randomized controlled pilot trial. Blood Purification. 2022; 1–10. doi: 10.1159/000526446

Kellum JA, Kong L, Fink MP, et al. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the genetic and inflammatory markers of sepsis (GenIMS) study. Archives of internal medicine. 2007; 167(15):1655–1663. doi: 10.1001/archinte.167.15.1655

Friesecke S, Träger K, Schittek GA, et al. International registry on the use of the CytoSorb adsorber in ICU patients : Study protocol and preliminary results. Medizinische Klinik Intensivmedizin und Notfallmedizin . 2019; 114(8):699–707. doi: 10.1007/s00063-017-0342-5

Ronco C, Bellomo R. Hemoperfusion: technical aspects and state of the art. Critical care (London, England). 2022; 26(1):135. doi: 10.1186/s13054-022-04009-w

Lu C, Hou N. Skin hyperpigmentation in coronavirus disease 2019 patients: Is polymyxin b the culprit? Frontiers in pharmacology. 2020; 11:01304–. doi: 10.3389/fphar.2020.01304

Ronco C, Reis T, De Rosa S. Coronavirus epidemic and extracorporeal therapies in intensive care: si vis pacem para bellum. Blood Purification. 2020; 49(3):255–8. doi:10.1159/000507039

Srisawat N, Tungsanga S, Lumlertgul N, et al. The effect of polymyxin b hemoperfusion on modulation of human leukocyte antigen DR in severe sepsis patients. Critical care (London, England). 2018; 22(1):279. doi: 10.1186/s13054-018-2077-y

Johansson PI, Windelov NA, Rasmussen LS, et al. Blood levels of histone-complexed DNA fragments are associated with coagulopathy, inflammation and endothelial damage early after trauma. Journal of emergencies, trauma, and shock . 2013; 6(3):171–175. doi: 10.4103/0974-2700.115327

Nishibori M, Takahashi HK, Katayama H, et al. Specific removal of monocytes from peripheral blood of septic patients by polymyxin b- immobilized filter column. Acta medica Okayama. 2009; 63(1):65–9. doi: 10.18926/AMO/31855

Abe S, Seo Y, Hayashi H, et al. Neutrophil adsorption by polymyxin b-immobilized fiber column for acute exacerbation in patients with interstitial pneumonia: A pilot study. Blood Purification. 2010; 29(4):321–326. doi: 10.1159/000287232

Ishiwari M, Togashi Y, Takoi H, et al. Polymyxin b haemoperfusion treatment for respiratory failure and hyperferritinaemia due to COVID- 19. Respirology case reports. 2020; 8(9):e00679. doi: 10.1002/rcr2.679

Katagiri D, Ishikane M, Asai Y, et al. Direct hemoperfusion using a polymyxin b-immobilized polystyrene column for COVID-19. Journal of clinical apheresis. 2021; 36(3):313–321. doi: 10.1002/jca.21861

De Rosa S, Cutuli SL, Ferrer Ret al. Polymyxin b hemoperfusion in coronavirus disease 2019 patients with endotoxic shock: Case series from EUPHAS2 registry. Artificial organs. 2021; 45(6):E187–E194. doi: 10.1111/ aor.13900

Guan M, Wang H, Tang X, et al. Continuous renal replacement therapy with adsorbing filter oXiris in acute kidney injury with septic shock: A retrospective observational study. Frontiers in medicine. 2022; 9:789623. doi: 10.3389/fmed.2022.789623

Niazi NS, Nassar TI, Stewart IJ, et al. A review of extracorporeal blood purification techniques for the treatment of critically ill coronavirus disease 2019 patients. ASAIO journal (American Society for Artificial Internal Organs . 1992; 68(10):1219–1227 doi: 10.1097/MAT.0000000000001761.

Zang S, Chen Q, Zhang Y, Xu L, Chen J. Comparison of the clinical effectiveness of AN69-oXiris versus AN69-ST filter in septic patients: A single-centre study. Blood Purification. 2021; 51(7):617–629. doi: 10.1159/000519166

Padala SA, Vakiti A, White JJ, et al. First reported use of highly adsorptive hemofilter in critically ill COVID-19 patients in the USA. Journal of clinical medicine research. 2020; 12(7):454–457. doi: 10.14740/jocmr4228

Zhang H, Zhu G, Yan L, et al. The absorbing filter oxiris in severe coronavirus disease 2019 patients: A case series. Artificial organs. 2020; 44(12):1296–1302. doi:10.1111/aor.13786

Premuzić V, Babel J, Gardijan D, et al. Extracorporeal blood purification is associated with improvement in biochemical and clinical variables in the critically-ill COVID-19 patients. Ther Apheresis Dialysis. 2022; 26(2):316–329. doi: 10.1111/1744-9987.13730

Rosalia RA, Ugurov P, Neziri D, et al. Extracorporeal blood purification in moderate and severe COVID-19 patients: A prospective cohort study. Blood Purification. 2022; 51(3):233–242. doi:10.1159/000515627

Villa G, Romagnoli S, De Rosa S, et al. Blood purification therapy with a hemodiafilter featuring enhanced adsorptive properties for cytokine removal in patients presenting COVID-19: A pilot study. Critical care (London, England). 2020; 24(1):605. doi: 10.1186/s13054-020-03322-6

Kang K, Luo Y, Gao Y, et al. Continuous renal replacement therapy with oXiris filter may not be an effective resolution to alleviate cytokine release syndrome in non-AKI patients with severe and critical COVID-19. Frontiers in pharmacology. 2022; 13:817793. doi: 10.3389/fphar.2022.817793

Khadzhynov D, von dem Berge U, Muench F, et al. Efficacy and complications of regional citrate anticoagulation during continuous renal replacement therapy in critically ill patients with COVID-19. Journal of critical care. 2022;67:126–131. doi: 10.1016/j.jcrc.2021.10.010

Chiao C, Faust H, Singh T. Regional citrate and systemic heparin are adequate to maintain filter half-life for COVID-19 patients on continuous renal replacement therapy. Seminars in dialysis. 2022; 35(4):325‐329. doi: 10.1111/sdi.13061

Siew LY, Lee ZY, Yunos NM et al. Outcomes of extracorporeal blood purification with oXiris® membrane in critically ill patients: a systematic review and meta-analysis. Journal of critical care. 2024; 83:154844. https://doi. org/10.1016/j.jcrc.2024.154844

Monard C, Rimmele’ T, Ronco C. Extracorporeal blood purification therapies for sepsis. Blood Purification. 2019; 47(Suppl 3):1–14. doi: 10.1159/000499520

Bermejo-Martin JF, Gonza’lez-Rivera M, Almansa R, et al. Viral RNA load in plasma is associated with critical illness and dysregulated host response in COVID-19. Critical care (London, England. 2020; 24(1):691.doi: 10.1186/s13054-020-03398-0

Kielstein JT, Borchina DN, Fühner T, et al. Hemofiltration with the seraph(®) 100 microbind(®) affinity filter decreases SARS-CoV-2 nucleocapsid protein in critically ill COVID-19 patients. Critical care (London, England). 2021; 25(1):190. doi: 10.1186/s13054-021-03597-3

Kelly MM, Wilkinson JD, Rastegar M, et al. Two patients with severe COVID pneumonia treated with the seraph-100 microbind affinity blood filter. Journal of intensive care medicine. 2021; 36(10):1228–1232. doi: 10.1177/08850666211039744

Pape A, Kielstein JT, Krüger T, et al. Treatment of a critically ill COVID-19 patient with the seraph 100 microbind affinity filter. TH open : companion journal to thrombosis and haemostasis. 2021; 5(2):e134–e138. doi: 10.1055/s-0041-1727121

Rifkin BS, Stewart IJ. Seraph-100 hemoperfusion in SARS-CoV-2-Infected patients early in critical illness: A case series. Blood Purification. 2022; 51(4):317–320. doi: 10.1159/ 000517430